[1]
|
National Cancer Institute. Cancer Statistics. https://seer.cancer.gov/statfacts/html/corp.html
|
[2]
|
Zhao, Y., Zhao, Q., Kaboli, P.J., Shen, J., Li, M., Wu, X., Yin, J., Zhang, H., Wu, Y., Lin, L., Zhang, L., Wan, L., Wen, Q., Li, X., Cho, C.H., Yi, T., Li, J. and Xiao, Z. (2019) m1A Regulated Genes Modulate PI3K/AKT/mTOR and ErbB Pathways in Gastrointestinal Cancer. Translational Oncology, 12, 1323-1333. https://doi.org/10.1016/j.tranon.2019.06.007
|
[3]
|
Freis, P., Bollard, J., Lebeau, J., Massoma, P., Fauvre, J., Vercherat, C., Walter, T., Manie, S., Roche, C., Scoazec, J.Y. and Ferraro-Peyret, C. (2017) mTOR Inhibitors Activate PERK Signaling and Favor Viability of Gastrointestinal Neuroendocrine Cell Lines. Oncotarget, 8, 20974-20987. https://doi.org/10.18632/oncotarget.15469
|
[4]
|
Li, J.C., Zhu, H.Y., Chen, T.X., Zou, L.Y., Wang, X.Y., Zhao, H.C. and Xu, J. (2013) Roles of mTOR and p-mTOR in Gastrointestinal Stromal Tumors. Asian Pacific Journal of Cancer Prevention, 14, 5925-5928. https://doi.org/10.7314/APJCP.2013.14.10.5925
|
[5]
|
Malley, C.O. and Pidgeon, G.P. (2016) The mTOR Pathway in Obesity Driven Gastrointestinal Cancers: Potential Targets and Clinical Trials. BBA Clinical, 5, 29-40. https://doi.org/10.1016/j.bbacli.2015.11.003
|
[6]
|
Cao, S., Cao, R., Liu, X., Luo, X. and Zhong, W. (2016) Design, Synthesis and Biological Evaluation of Novel Benzothiazole Derivatives as Selective PI3Kbeta Inhibitors. Molecules, 21, 876-890. https://doi.org/10.3390/molecules21070876
|
[7]
|
Yang, H., Rudge, D.G., Koos, J.D., Vaidialingam, B., Yang, H.J. and Pavletich, N.P. (2013) mTOR Kinase Structure, Mechanism and Regulation. Nature, 497, 217-223. https://doi.org/10.1038/nature12122
|
[8]
|
Hay, N. and Sonenberg, N. (2004) Upstream and Downstream of mTOR. Genes & Development, 18, 1926-1945. https://doi.org/10.1101/gad.1212704
|
[9]
|
Bertelsen, B.I., Steine, S.J., Sandvei, R., Molven, A. and Laerum, O.D. (2006) Molecular Analysis of the PI3K-AKT Pathway in Uterine Cervical Neoplasia: Frequent PIK3CA Amplification and AKT Phosphorylation. International Journal of Cancer, 118, 1877-1883. https://doi.org/10.1002/ijc.21461
|
[10]
|
Kahn, J., Hayman, T.J., Jamal, M., Rath, B.H., Kramp, T., Camphausen, K. and Tofilon, P.J. (2014) The mTORC1/mTORC2 Inhibitor AZD2014 Enhances the Radiosensitivity of Glioblastoma Stem-Like Cells. Neuro-Oncology, 16, 29-37. https://doi.org/10.1093/neuonc/not139
|
[11]
|
Hayman, T.J., Wahba, A., Rath, B.H., Bae, H., Kramp, T., Shankavaram, U.T., Camphausen, K. and Tofilon, P.J. (2014) The ATP-Competitive mTOR Inhibitor INK128 Enhances in Vitro and in Vivo Radiosensitivity of Pancreatic Carcinoma Cells. Clinical Cancer Research, 20, 110-119. https://doi.org/10.1158/1078-0432.CCR-13-2136
|
[12]
|
Li, A., Zhang, R., Zhang, Y., Liu, X., Wang, R., Liu, J., Liu, X., Xie, Y., Cao, W., Xu, R., Ma, Y., Cai, W., Wu, B., Cai, S. and Tang, X. (2019) BEZ235 Increases Sorafenib Inhibition of Hepatocellular Carcinoma Cells by Suppressing the PI3K/AKT/mTOR Pathway. American Journal of Translational Research, 11, 5573-5585.
|
[13]
|
Li, S., Liang, Y., Wu, M., Wang, X., Fu, H., Chen, Y. and Wang, Z. (2013) The Novel mTOR Inhibitor CCI-779 (Temsirolimus) Induces Antiproliferative Effects through Inhibition of mTOR in Bel-7402 Liver Cancer Cells. Cancer Cell International, 13, 30. https://doi.org/10.1186/1475-2867-13-30
|
[14]
|
Serova, M., de Gramont, A., Tijeras-Raballand, A., Dos Santos, C., Riveiro, M.E., Slimane, K., Faivre, S. and Raymond, E. (2013) Benchmarking Effects of mTOR, PI3K, and Dual PI3K/mTOR Inhibitors in Hepatocellular and Renal Cell Carcinoma Models Developing Resistance to Sunitinib and Sorafenib. Cancer Chemotherapy and Pharmacology, 71, 1297-1307. https://doi.org/10.1007/s00280-013-2129-6
|
[15]
|
Yu, K., Shi, C., Toral-Barza, L., Lucas, J., Shor, B., Kim, J.E., Zhang, W.-G., Mahoney, R., Gaydos, C., Tardio, L., Kim, S.K., Conant, R., Curran, K., Kaplan, J., Verheijen, J., Ayral-Kaloustian, S., Mansour, T.S., Abraham, R.T., Zask, A. and Gibbons, J.J. (2010) Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2. Cancer Research, 70, 621-631. https://doi.org/10.1158/0008-5472.CAN-09-2340
|
[16]
|
Luo, J., Pi, G., Xiao, H., Ye, Y., Li, Q., Zhao, L., Huang, H., Luo, H., Zhang, Q., Wang, D. and Wang, G. (2018) Torin2 Enhances the Radiosensitivity of MCF7 Breast Cancer Cells by Down-Regulating the mTOR Signaling Pathway and ATM Phosphorylation. Molecular Medicine Reports, 17, 366-373. https://doi.org/10.3892/mmr.2017.7848
|
[17]
|
Tonlaar, N., Galoforo, S., Thibodeau, B.J., Ahmed, S., Wilson, T.G., Yumpo Cardenas, P., Marples, B. and Wilson, G.D. (2017) Antitumor Activity of the Dual PI3K/MTOR Inhibitor, PF-04691502, in Combination with Radiation in Head and Neck Cancer. Radiotherapy and Oncology, 124, 504-512. https://doi.org/10.1016/j.radonc.2017.08.001
|
[18]
|
Wainberg, Z.A., Soares, H.P., Patel, R., DiCarlo, B., Park, D.J., Liem, A., Wang, H.J., Yonemoto, L., Martinez, D., Laux, I., Brennan, M. and Hecht, J.R. (2015) Phase II Trial of Everolimus in Patients with Refractory Metastatic Adenocarcinoma of the Esophagus, Gastroesophageal Junction and Stomach: Possible Role for Predictive Biomarkers. Cancer Chemotherapy and Pharmacology, 76, 61-67. https://doi.org/10.1007/s00280-015-2744-5
|
[19]
|
Park, J.H., Ryu, M.H., Park, Y.S., Park, S.R., Na, Y.S., Rhoo, B.Y. and Kang, Y.K. (2015) Successful Control of Heavily Pretreated Metastatic Gastric Cancer with the mTOR Inhibitor Everolimus (RAD001) in a Patient with PIK3CA Mutation and pS6 Overexpression. BMC Cancer, 15, Article No. 119. https://doi.org/10.1186/s12885-015-1139-7
|
[20]
|
Doi, T., Muro, K., Boku, N., Yamada, Y., Nishina, T., Takiuchi, H., Komatsu, Y., Hamamoto, Y., Ohno, N., Fujita, Y., Robson, M. and Ohtsu, A. (2010) Multicenter Phase II Study of Everolimus in Patients with Previously Treated Metastatic Gastric Cancer. Journal of Clinical Oncology, 28, 1904-1910. https://doi.org/10.1200/JCO.2009.26.2923
|
[21]
|
Shen, Y.C., Li, C.P., Yen, C.J., Hsu, C., Lin, Y.L., Lin, Z.Z., Chen, L.T., Su, W.C., Chao, Y., Yeh, K.H. and Cheng, A.L. (2014) Phase II Multicentered Study of Low-Dose Everolimus plus Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin as First-Line Treatment for Patients with Advanced Gastric Cancer. Oncology, 87, 104-113. https://doi.org/10.1159/000362671
|
[22]
|
Yoon, D.H., Ryu, M.H., Park, Y.S., Lee, H.J., Lee, C., Ryoo, B.Y., Lee, J.L., Chang, H.M., Kim, T.W. and Kang, Y.K. (2012) Phase II Study of Everolimus with Biomarker Exploration in Patients with Advanced Gastric Cancer Refractory to Chemotherapy Including Fluoropyrimidine and Platinum. British Journal of Cancer, 106, 1039-1044. https://doi.org/10.1038/bjc.2012.47
|
[23]
|
Lee, S.J., Lee, J., Lee, J., Park, S.H., Park, J.O., Park, Y.S., Lim, H.Y., Kim, K.M., Do, I.G., Jung, S.H., Yim, D.S. and Kang, W.K. (2013) Phase II Trial of Capecitabine and Everolimus (RAD001) Combination in Refractory Gastric Cancer Patients. Investigational New Drugs, 31, 1580-1586. https://doi.org/10.1007/s10637-013-0022-0
|
[24]
|
Ohtsu, A., Ajani, J.A., Bai, Y.X., Bang, Y.J., Chung, H.C., Pan, H.M., Sahmoud, T., Shen, L., Yeh, K.H., Chin, K., Muro, K., Kim, Y.H., Ferry, D., Tebbutt, N.C., Al-Batran, S.E., Smith, H., Costantini, C., Rizvi, S., Lebwohl, D. and Van Cutsem, E. (2013) Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study. Journal of Clinical Oncology, 31, 3935-3943. https://doi.org/10.1200/JCO.2012.48.3552
|
[25]
|
Zaller, N. and Brinkley-Rubinstein, L. (2018) Incarceration, Drug Use, and Infectious Diseases: A Syndemic Still Not Addressed. The Lancet Infectious Diseases, 18, 1301-1302. https://doi.org/10.1016/S1473-3099(18)30538-3
|
[26]
|
Feng, F., Jiang, Q., Cao, S., Cao, Y., Li, R., Shen, L., Zhu, H., Wang, T., Sun, L., Liang, E., Sun, H., Chai, Y., Li, X., Liu, G., Yang, R., Yang, Z., Yang, Y., Xin, S. and Li, B.A. (2018) Pregnane X Receptor Mediates Sorafenib Resistance in Advanced Hepatocellular Carcinoma. Biochimica et Biophysica Acta—General Subjects, 1862, 1017-1030. https://doi.org/10.1016/j.bbagen.2018.01.011
|
[27]
|
Xie, X., Hu, H., Tong, X., Li, L., Liu, X., Chen, M., Yuan, H., Xie, X., Li, Q., Zhang, Y., Ouyang, H., Wei, M., Huang, J., Liu, P., Gan, W., Liu, Y., Xie, A., Kuai, X., Chirn, G.W., Zhou, H., Zeng, R., Hu, R., Qin, J., Meng, F.L., Wei, W., Ji, H. and Gao, D. (2018) The mTOR-S6K Pathway Links growth Signalling to DNA Damage Response by Targeting RNF168. Nature Cell Biology, 20, 320-331. https://doi.org/10.1038/s41556-017-0033-8
|
[28]
|
Zhang, C.Z., Wang, X.D., Wang, H.W., Cai, Y. and Chao, L.Q. (2015) Sorafenib Inhibits Liver Cancer Growth by Decreasing mTOR, AKT, and PI3K Expression. Journal of BUON, 20, 218-222.
|
[29]
|
Geissler, E.K., Schnitzbauer, A.A., Zulke, C., Lamby, P.E., Proneth, A., Duvoux, C., Burra, P., Jauch, K.W., Rentsch, M., Ganten, T.M., Schmidt, J., Settmacher, U., Heise, M., Rossi, G., Cillo, U., Kneteman, N., Adam, R., van Hoek, B., Bachellier, P., Wolf, P., Rostaing, L., Bechstein, W.O., Rizell, M., Powell, J., Hidalgo, E., Gugenheim, J., Wolters, H., Brockmann, J., Roy, A., Mutzbauer, I., Schlitt, A., Beckebaum, S., Graeb, C., Nadalin, S., Valente, U., Turrion, V.S., Jamieson, N., Scholz, T., Colledan, M., Fandrich, F., Becker, T., Soderdahl, G., Chazouilleres, O., Makisalo, H., Pageaux, G.P., Steininger, R., Soliman, T., de Jong, K.P., Pirenne, J., Margreiter, R., Pratschke, J., Pinna, A.D., Hauss, J., Schreiber, S., Strasser, S., Klempnauer, J., Troisi, R.I., Bhoori, S., Lerut, J., Bilbao, I., Klein, C.G., Konigsrainer, A., Mirza, D.F., Otto, G., Mazzaferro, V., Neuhaus, P. and Schlitt, H.J. (2016) Sirolimus Use in Liver Transplant Recipients with Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation, 100, 116-125. https://doi.org/10.1097/TP.0000000000000965
|
[30]
|
Chang, L., Graham, P.H., Ni, J., Hao, J., Bucci, J., Cozzi, P.J. and Li, Y. (2015) Targeting PI3K/Akt/mTOR Signaling Pathway in the Treatment of Prostate Cancer Radioresistance. Critical Reviews in Oncology/Hematology, 96, 507-517. https://doi.org/10.1016/j.critrevonc.2015.07.005
|
[31]
|
Li, B., Yang, J., Lu, Z., Liu, B. and Liu, F. (2019) A Study on the Mechanism of Rapamycin Mediating the Sensitivity of Pancreatic Cancer Cells to Cisplatin through PI3K/AKT/mTOR Signaling Pathway. Journal of BUON, 24, 739-745.
|
[32]
|
Fazio, N., Buzzoni, R., Baudin, E., Antonuzzo, L., Hubner, R.A., Lahner, H., WW, D.E.H., Raderer, M., Teule, A., Capdevila, J., Libutti, S.K., Kulke, M.H., Shah, M., Dey, D., Turri, S., Aimone, P., Massacesi, C. and Verslype, C. (2016) A Phase II Study of BEZ235 in Patients with Everolimus-Resistant, Advanced Pancreatic Neuroendocrine Tumours. Anticancer Research, 36, 713-719.
|
[33]
|
Wang, H., Wang, X., Xu, L., Zhang, J. and Cao, H. (2019) A Molecular Sub-Cluster of Colon Cancer Cells with Low VDR Expression Is Sensitive to Chemotherapy, BRAF Inhibitors and PI3K-mTOR Inhibitors Treatment. Aging (Albany NY), 11, 8587-8603. https://doi.org/10.18632/aging.102349
|
[34]
|
Liu, Y., Starr, M.D., Brady, J.C., Rushing, C., Bulusu, A., Pang, H., Honeycutt, W., Amara, A., Altomare, I., Uronis, H.E., Hurwitz, H.I. and Nixon, A.B. (2015) Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus. Molecular Cancer Therapeutics, 14, 1048-1056. https://doi.org/10.1158/1535-7163.MCT-14-0923-T
|